Related Experiment Video
Updated: Jul 19, 2026
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
PMA and doxorubicin decrease viability, MTT activity and expression of CD10 marker on NALM-1 leukemic cells
I Martin-Kleiner1, I Svoboda-Beusan, J Gabrilovac
1Division of Molecular Medicine, Ruder Bosković Institute, Zagreb, Croatia. kleiner@irb.hr
Abstract:
PMA (10, 20 ng/ml) and doxorubicin (5-20 ng/ml) decreased the viability and MTT-activity of NALM-1 pre-B leukemic cells (3 days' treatment). Further, CD10 was downregulated, suggesting that PMA and doxorubicin induced differentiation of NALM-1 cells. However, PMA did not alter expression of B cell markers CD20 and of mIgM. In contrast to PMA, another differentiation agent ATRA did not alter CD10 expression on NALM-1 cells but affected viability after 6 days (5, 10 ng/ml). The data in this study are the first evidence that PMA and doxorubicin inhibited viability and MTT activity and induced partial differentiation, by decreasing CD10 on NALM-1 cells.
Insights
Phorbol 12-myristate 13-acetate (PMA) and doxorubicin reduce viability and induce partial differentiation in NALM-1 leukemic cells by downregulating CD10. These findings offer new insights into leukemia treatment strategies.
Area of Science:
- * Hematology
- * Cell Biology
- * Cancer Research
Background:
- * Pre-B acute lymphoblastic leukemia (ALL) is a significant hematologic malignancy.
- * Understanding cellular differentiation pathways is crucial for developing targeted therapies.
- * NALM-1 cells are a relevant model for studying pre-B ALL progression and treatment responses.
Purpose of the Study:
- * To investigate the effects of Phorbol 12-myristate 13-acetate (PMA) and doxorubicin on NALM-1 cell viability and differentiation.
- * To determine the impact of these agents on specific cell surface markers, including CD10, CD20, and mIgM.
- * To compare the differentiation-inducing effects of PMA with another agent, ATRA (all-trans retinoic acid).
Main Methods:
- * Treatment of NALM-1 pre-B leukemic cells with varying concentrations of PMA and doxorubicin for 3 days.
- * Assessment of cell viability and MTT activity.
- * Analysis of cell surface marker expression (CD10, CD20, mIgM) using flow cytometry or similar techniques.
Main Results:
- * PMA and doxorubicin significantly decreased NALM-1 cell viability and MTT activity.
- * Both agents led to the downregulation of CD10 expression, indicating partial cellular differentiation.
- * PMA did not affect CD20 or mIgM expression, while ATRA impacted viability but not CD10 expression.
Conclusions:
- * PMA and doxorubicin demonstrate efficacy in inhibiting NALM-1 leukemic cell growth and inducing partial differentiation.
- * The downregulation of CD10 is a key indicator of PMA- and doxorubicin-induced differentiation in this cell line.
- * These findings provide novel evidence for the therapeutic potential of PMA and doxorubicin in targeting pre-B ALL.
